Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

Cardiorenal Syndrome Clinical Trial

Official title:

Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02372292
• Other study ID #: Ankararenal
• Status: Completed
• Phase: N/A
• First received: February 13, 2015
• Last updated: June 22, 2015
• Start date: February 2013
• Est. completion date: June 2015

Study information

• Verified date: June 2015
• Source: Ankara University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Although the traditional determinant of renal dysfunction in heart failure was suggested as decreased cardiac output and renal hypo perfusion, recent studies have demonstrated the association of persistent systemic venous congestion and kidney dysfunction. Relief of the congestion has demonstrated to improve renal functions in decompensated heart failure. The current trial was set up to investigate the changes of renal venous impedance and renal arteriolar resistivity indices with diuretic therapy, in patients with congestive renal failure. The investigators asked whether measurement of renal venous impedance index or renal arteriolar resistivity index can guide the practice of diuretic therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Decompensated heart failure

• Elevated serum creatinine levels on admission

Exclusion Criteria:

• Atrial fibrillation

• Obstructive uropathy

• Patients with ascites

• Patients who exposed the potential nephrotoxic drugs in the previous week (metformin, antibiotics, chemotherapeutics, iodinated contrast agents and non-steroidal anti-inflammatory agents)

• Patients who needed positive inotropic agents

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Cardio-Renal Syndrome
• Cardiorenal Syndrome
• Heart Failure

Intervention

Drug:
• intravenous furosemide
Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion

Locations

Country	Name	City	State
Turkey	Ankara University School Of Medicine, Department of Cardiology	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Ankara University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Alterations in the renal arterial resistivity index	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.	during hospitalization, an expected average of 4 weeks.	No
Secondary	Alterations in the renal venous impedance index	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.	during hospitalization, an expected average of 4 weeks.	No